Thiele, Maja; Wiest, Reiner; Gluud, Lise Lotte; Albillos, Agustín; Krag, Aleksander (2013). Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis? Medical hypotheses, 81(5), pp. 871-874. Elsevier 10.1016/j.mehy.2013.08.026
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
Can non-selective beta-blockers prevent hepatocellular carcinoma in.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (524kB) |
Hepatocellular carcinoma is the main liver-related cause of death in patients with compensated cirrhosis. The early phases are asymptomatic and the prognosis is poor, which makes prevention essential. We propose that non-selective beta-blockers decrease the incidence and growth of hepatocellular carcinoma via a reduction of the inflammatory load from the gut to the liver and inhibition of angiogenesis. Due to their effect on the portal pressure, non-selective beta-blockers are used for prevention of esophageal variceal bleeding. Recently, non-hemodynamic effects of beta-blockers have received increasing attention. Blockage of β-adrenoceptors in the intestinal mucosa and gut lymphatic tissue together with changes in type and virulence of the intestinal microbiota lead to reduced bacterial translocation and a subsequent decrease in the portal load of pathogen-associated molecular patterns. This may reduce hepatic inflammation. Blockage of β-adrenoceptors also decrease angiogenesis by inhibition of vascular endothelial growth factors. Because gut-derived inflammation and neo-angiogenesis are important in hepatic carcinogenesis, non-selective beta-blockers can potentially reduce the development and growth of hepatocellular carcinoma. Rodent and in vitro studies support the hypothesis, but clinical verification is needed. Different study designs may be considered. The feasibility of a randomized controlled trial is limited due to the necessary large number of patients and long follow-up. Observational studies carry a high risk of bias. The meta-analytic approach may be used if the incidence and mortality of hepatocellular carcinoma can be extracted from trials on variceal bleeding and if the combined sample size and follow up is sufficient.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology |
UniBE Contributor: |
Wiest, Reiner |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0306-9877 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Lilian Karin Smith-Wirth |
Date Deposited: |
11 Jun 2014 13:12 |
Last Modified: |
05 Dec 2022 14:34 |
Publisher DOI: |
10.1016/j.mehy.2013.08.026 |
Uncontrolled Keywords: |
BT, HCC, HCV, HVPG, LPS, NSBB, PAMP, TIPS, TLR4, Toll Like Receptor 4, VEGF, bacterial translocation, beta-adrenoceptors, hepatic venous pressure gradient, hepatitis C virus, hepatocellular carcinoma, lipopolysaccharide, non-selective beta-blockers, pathogen-associated molecular pattern, transjugular intrahepatic portosystemic shunt, vascular endothelial growth factor, β-AR |
BORIS DOI: |
10.7892/boris.53062 |
URI: |
https://boris.unibe.ch/id/eprint/53062 |
Actions (login required)
 |
Edit item |